Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-versus-host disease

Daniel de Almeida Borges1*, Marcos Rodrigo Alborghetti2, Adriana Franco Paes Leme3, Romenia Ramos Domingues3, Bruna Duarte1, Melina Veiga1, Marilia Trindade Ferrer1, Ana Claudia Viana Wanzeler1, Carlos Eduardo Leite Arieta1 and Monica Alves1

Abstract

Background: Diseases of the anterior segment of the eye may present different mechanisms, intensity of symptoms, and impact on the patients’ quality of life and vision. The tear film is in direct contact with the ocular surface and cornea and can be easily accessed for sample collection, figuring as a promising source of potential biomarkers for diagnosis and treatment control. This study aimed to evaluate tear proteomic profile in 3 distinct ocular diseases: keratoconus (corneal ectasia), severe dry eye related to graft-versus-host-disease (tear film dysfunction and ocular inflammatory condition) and pterygium (conjunctival fibrovascular degenerative disease).

Methods: Tear samples were collected from patients of each condition and a control group. By using mass spectrometric analysis combined with statistics and bioinformatics tools, a detailed comparison of protein profile was performed.

Results: After Student’s t-test analyses comparing each condition to the control group, we found the following number of differentially expressed proteins: 7 in keratoconus group, 29 in pterygium group, and 79 in GVHD group. Following multivariate analyses, we also report potential candidates as biomarkers for each disease.

Conclusions: We demonstrated herein that mass spectrometry-based proteomics was able to indicate proteins that differentiate three distinct ocular conditions, which is a promising tool for the diagnosis of ocular diseases.

Keywords: Keratoconus, Dry eye, Pterygium, Tear film, Proteomics

Background

Ocular surface diseases encompass a wide range of conditions associated with corneal and conjunctival structures, tear film imbalance and adnexal glands dysfunction. Distinct disorders may commone similar clinical presentation despite significant differences in pathophysiological mechanisms [1]. Tear fluid plays an essential role in the ocular surface through its lubricating properties and by providing nutrient supply and protection against infection and other hazards. Tear film complex composition contains proteins, such as enzymes, mucins, hormones, growth factors, neuropeptides, cytokines along with lipids, salts, and carbohydrates [2]. Ocular surface diseases carry profound variations on tear contents. Tears can be easily accessed and collected through minimally invasive methods; thus its analysis represents a promising approach for diagnosis and monitoring of human ocular surface diseases [3].

Proteomic analysis of human fluids has become one of the most relevant approaches for disease biomarkers.
research [4]. Proteome patterns in tears offer a powerful analytical tool to understand proper protein function in homeostasis as well as in underlying disease processes, and to provide biomarkers. Several studies have previously investigated tear proteomics in ocular diseases such as dry eye [5–7], keratoconus [8–10], and graft-versus-host-disease (GVHD) [11].

Three distinct ocular conditions were chosen for the tear proteomic comparison: keratoconus, severe dry eye related to graft-versus-host-disease (GVHD), and pterygium. Keratoconus is a primary corneal ectatic disease associated with progressive stromal thinning and protrusion leading to visual impairment. Prevalence varies from 8.8 to 229, and reported incidence ranges from 1.3 to 25 per 100,000 per year [12, 13]. Dry Eye Disease (DED) is a common, complex and multifactorial disease of the ocular surface and tear film that results in discomfort and visual disturbance [14]. Severe forms such as seen in chronic GVHD are a major complication after allogeneic stem cell transplantation and can lead to significant morbidity [15]. Pterygium is an ocular surface disorder with a higher incidence in tropical climates, consisting of a non-neoplastic elastotic degeneration of the bulbar conjunctiva that extends to the corneal surface, and is mainly associated to long-term ultraviolet radiation exposure [16].

All these conditions—keratoconus, pterygium, and chronic GVHD dry eye—can significantly alter the ocular surface and tear film parameters [15, 17, 18]. This pilot study aimed to compare the tear proteomic profile in these distinct ocular disorders and report possible biomarkers.

Methods

The study was carried out with the approval of the Institutional Research Ethics Committee Board and was conducted under the tenets of the Declaration of Helsinki and current legislation on clinical research. Written informed consent was obtained from all subjects after explanation of the procedures and study requirements.

A total of 29 study subjects were recruited at the Ambulatory of Ophthalmology, Clinical Hospital of the University of Campinas (UNICAMP).

Study subjects were divided into four groups: 4 patients with keratoconus, 9 patients with pterygium, 10 patients with GVHD, and 6 normal controls. Each participant was submitted to a broad clinical examination, including ocular surface evaluation and corneal tomographic imaging. Keratoconus diagnosis was confirmed by imaging evaluation showing characteristic corneal steepening, thinning, altered corneal elevation maps, and irregular astigmatism [13]. Pterygium diagnosis was based on the clinical presentation at slip lamp examination of a fibrovascular proliferation of the bulbar conjunctiva related to irritative symptoms [19]. Dry-eye related chronic ocular GVHD was confirmed through a comprehensive evaluation of tear film and ocular surface parameters, such as tear film break up time, Schirmer test, corneal staining, tear meniscus height, in patients with prior hematopoietic stem cell transplantation [15]. Inclusion criteria for the control group were corneal tomographic maps and indices within the normal range, ocular surface parameters within the normal range, and no clinical sign of pterygium or any other ocular surface disease.

Tear samples were collected using a micropipette after a flush of sterile distilled water (20 µL) over the eye surface, and then they were transferred to Eppendorf tubes and frozen at −80 °C.

Sample preparation

Tear samples were thawed in ice, and a final volume of 15 µL was used for digestion. In sequence, we added a volume 1:1 of urea 8 M. Samples were reduced with the addition of 5 mM final concentration of DTT (DL-Dithiothreitol—Sigma-Aldrich®) and incubated for 25 min at 56 °C, and then alkylated with 14 mM final concentration of IAA (Iodoacetamide—SigmaAldrich®), for 30 min at room temperature and in the dark. After these steps, we added 1 mM of CaCl² (Synth®), followed by digestion with 0.3 µg of trypsin (Sequencing Grade Modified Trypsin, V5111, Promega) for 16 h at 37 °C. After digestion with trypsin, its reaction was interrupted with the addition of formic acid at 1% (Merck®), with a pH of less than 3. In sequence, samples were desalted with Stage Tips with C18 membranes (Octadeyl C18-bonded silica—3 M Empore™ extraction disks) and then completely dried (SPD 1010 SpeedVac®, Thermo) [20].

Liquid chromatography–mass spectrometry (LC–MS) sample injection

A 2 µL aliquot from each sample was analyzed in the mass spectrometer LTQ Orbitrap Velos (Thermo Fisher Scientific) coupled with the liquid chromatography system EASYnLC II (Proxeon) through a nanoelectrospray interface. Peptides were separated by a 2–90% acetonitrile gradient in 0.1% formic acid using an analytical PicoFrit Column (20 cm × ID75 µm, 5 µm particle size, New objective) at a flow rate of 300 nL/min over 80 min. The nanoelectrospray voltage was set to 2.2 kV, and the source temperature was 275 °C. The 20 most intense ions were chosen for CID collision-induced dissociation (CID) fragmentation, based on a data-dependent analysis. The full scan mass spectrometry (MS) spectra (m/z 300–1600) were acquired in the Orbitrap analyzer after accumulation to a target value of 1e6. The resolution in the Orbitrap was set to r = 60,000, and the most intense
peaks were fragmented by CID with a normalized collision energy of 35% and activation time of 10 ms. The signal threshold for triggering an MS/MS event was set to 1000 counts, with a dynamic exclusion of 60 s.

Pre-processing
After data acquisition, we performed data processing with the Andromeda algorithm within the MaxQuant version 1.3.0.3 software against the UniProt Human Protein Database (Release: March 2017, 92,934 sequences and 36,874,315 residues).

Bioinformatic analysis was performed using Perseus version 1.5.1.6 software. We used logarithmic transformation and application of filters to exclude proteins with reverse sequences, proteins identified by only one modified peptide, and filtering by minimum valid values of 5 in at least one group.

Statistical analysis
MS data were log2 transformed before statistical analysis. Univariate analyses were performed on GraphPad Prism version 6.00. Samples measurements from patients with GVHD, pterygium or keratoconus were compared to respective control samples by Student’s t-test, not paired and without or with correction for multiple analyses (FDR 5%, FDR 1% or Holm-Sidak method). Multivariate analyses were performed on online platform Metaboanalyst (https://www.metaboanalyst.ca). Top 10 features for pterygium and top 8 features from VIP-PLSDA (Variable Importance in Projection in Partial Least Scores Discriminant Analysis) score for GVHD and keratoconus were selected for heat map visualization, clustering and receiver operating characteristic (ROC) analyses. For heat map visualization, data was auto-scaled. Distance measurement was Euclidean, and clustering algorithm was Ward. The area under curve (AUC) from multivariate ROC analyses and corresponding to 95% confidence intervals were calculated to estimate the clinical potential of selected metabolites as biomarkers [21].

Biochemical pathways prospection
Proteins with p-value < 0.05 in Student’s t-test analyses were selected, and biochemical pathways prospections were performed for each disease on KEGG Mapper/Search Pathway (https://www.kegg.jp/kegg/tool/map_pathway1.html), last updated: June 10, 2014) against Homo sapiens database [22].

Results
Clinical characteristics of each study group are presented in Table 1.

Table 1 Clinical characteristics of each study group

| Group    | n  | Age (years, mean) | Sex (female: male ratio) |
|----------|----|-------------------|--------------------------|
| Keratoconus | 4  | 30.5              | 2:2                      |
| Pterygium | 9  | 47.2              | 3:6                      |
| GVHD     | 10 | 49.6              | 7:3                      |
| Control  | 6  | 47.5              | 5:1                      |

Proteins identification and quantification
The MS quantification analysis identified a total of 208 distinct proteins in the tear samples from keratoconus group, 332 proteins in the pterygium group, and 517 proteins in the GVHD group (Additional file 1: Table S1; Additional file 2: Table S2; Additional file 3: Table S3). The relationship between the tear proteomes analyzed in our study is shown in Fig. 1a, b. The total number of distinct proteins identified for each disease is shown, and Venn diagram displays the number of overlapping proteins in the three proteomes, in which proteins in common are shown in the intersection between the circles. As can be observed in Fig. 1b, the total number of identified proteins for the control group differ between groups, because in the spectra preprocessing stage each disease was analyzed separately. This is necessary to avoid interference of a specific disease in another and artifact production. In this process, FDR is applied for each comparison causing slight differences in the number of identified proteins. Consequently, different numbers of proteins were found for each pair of disease versus control group. This also prevents the inclusion of the control group in the three disease’s Venn diagram in Fig. 1a.

Biochemical pathways prospection
After t-test statistical analyses, 7 proteins were found with increased levels in the keratoconus group comparing to controls, as shown in Table 2. None of these proteins retained statistical significance after multiple comparisons correction. The analysis did not show any protein with decreased levels in the keratoconus group.

After Student’s t-test analyses comparing pterygium group versus control, 29 proteins showed altered expression, 9 with decreased levels and 20 with increased levels comparing to controls, as shown in Tables 3 and 4. After multiple comparisons correction, 2 proteins with increased levels retained statistical significance with 5% false discovery rate (FDR) and 1 protein with family-wise error rate (FWER) using the Holm-Sidak method.

After Student’s t-test analyses, 79 proteins showed altered expression in the GVHD group comparing to controls, 35 proteins with decreased levels and 44 with increased levels. Among the proteins with decreased
levels, after multiple comparisons correction, 19 proteins retained statistical significance with 5% FDR, 6 proteins with 1% FDR, and 2 proteins with FWER using the Holm-Sidak method (Table 5). Among the proteins with increased levels, after multiple comparisons correction, 17 proteins retained statistical significance with 5% FDR, and 3 proteins with both 1% FDR and FWER using the Holm-Sidak method (Table 6).

Figure 1a (to the right) shows the number of differentially expressed proteins with p < 0.05 after Student’s t-test analyses in the three disease groups compared to controls. There is one protein in common between all groups (Keratin, type I cytoskeletal 13, increased level); another protein in common between keratoconus and pterygium group (Immunoglobulin heavy variable 5-10-1, increased level); 2 more proteins in common between keratoconus and GVHD group (Neutrophil defensin and Immunoglobulin mu chain C region, increased levels); and another 9 proteins in common between GVHD and pterygium groups (Keratin, type I cytoskeletal 14, Keratin, type II cytoskeletal 5, Keratin, type II cytoskeletal 4, Uroplakin-3b-like protein, Heat shock cognate 71 kDa protein, Myosin light polypeptide 6, Annexin A2, 14-3-3 protein zeta/delta, increased levels, and Prolactin-inducible protein, decreased level).

The biochemical pathway prospection performed on the KEGG mapper for the pterygium tear proteome is shown in Fig. 2, which represents the estrogen signaling pathway, with altered proteins highlighted: increased levels of KRT13 (Keratin, type I cytoskeletal 13) and HSPA8.
From GVHD tear protein profile, biochemical pathway prospection retrieved the complement and coagulation cascades (Fig. 3), with altered proteins highlighted: increased levels of KNG1 (Kininogen-1), A2M (Alpha-2-macroglobulin), PLG (Plasminogen), CFH (Complement factor H), CFB (Complement factor B), C3 (Complement C3), and C4BPA (C4b-binding protein alpha chain), and decreased level of CLU (Clusterin).

Biochemical pathway prospection for keratoconus did not yield significant results because of the low number of statistically significant proteins between keratoconus and control group in the univariate analysis.

Potential biomarkers
Heat map dendrographic profiles, PCA (principal component analysis) scores plot, and ROC (receiver operating characteristic) curves for the keratoconus group are shown in Fig. 4. PCA scores were 57.2% for PC1.
(principal component) and 16.4% for PC2. The area under curve (AUC) from multivariate ROC analyses and corresponding 95% confidence intervals are shown in Fig. 5. After these multivariate analyses, the top 8 features from VIP-PLSDA were chosen, the area under curve (AUC) from multivariate ROC analyses and corresponding to 95% confidence intervals were calculated, and the proteins identified as potential biomarkers are presented in decreasing order of average importance on Table 7.

Heat map dendrographic profiles, PCA scores plot, and ROC curves for pterygium group are shown in Fig. 6. PCA scores were 61.7% for PC1 and 11.4% for PC2. The area under curve from multivariate ROC analyses and corresponding 95% confidence intervals are shown in Fig. 7. After these multivariate analyses, the top 10 features from VIP-PLSDA were chosen, the area under curve (AUC) from multivariate ROC analyses and corresponding to 95% confidence intervals were calculated, and the proteins identified as potential biomarkers are presented in decreasing order of average importance on Table 8.

Heat map dendrographic profiles, PCA scores plot, and ROC curves for the GVHD group are shown in Fig. 8. PCA scores were 76.5% for PC1 and 8.9% for PC2. The area under curve from multivariate ROC analyses and corresponding 95% confidence intervals are shown in Fig. 9. After these multivariate analyses, the top 8 features from VIP-PLSDA were chosen, the area under curve (AUC) from multivariate ROC analyses and corresponding to 95% confidence intervals were calculated, and the proteins identified as potential biomarkers are presented in decreasing order of average importance on Table 9.

Discussion
Tear film of three different ocular diseases—keratoconus, pterygium, and chronic GVHD related dry eye—were analyzed using LC–MS for quantitative proteomic investigation. Each group was compared to a control group, and each disease displayed distinct proteome profile.
**Table 5** Student’s t-test analysis of tear proteome from patients diagnosed with ocular GVHD versus control

| Gene name | Protein                                                                 | p-value    | FDR 5% | FDR 1% | FWER | Control average LFQ log transformed | GVHD average LFQ log transformed | SE of difference |
|-----------|-------------------------------------------------------------------------|------------|--------|--------|------|-------------------------------------|----------------------------------|------------------|
| LCN1      | Lipocalin-1                                                            | 6.92E-05   | Y      | Y      | Y    | 34.6                                | 25.2                             | 1.7              |
| TGM2      | Protein-glutamine gamma-glutamyltransferase 2                          | 9.48E-05   | Y      | Y      | Y    | 24.2                                | 21.7                             | 0.4              |
| LTF       | Lactotransferrin; Kaliocin-1; Lactoferrin-A; Lactoferrin-B; Lactoferrin-C | 1.97E-04   | Y      | Y      | N    | 35.4                                | 28.6                             | 1.4              |
| AZGP1     | Zinc-alpha-2-glycoprotein                                              | 2.29E-04   | Y      | Y      | N    | 32.3                                | 28.9                             | 0.7              |
| CRISP3    | Cysteine-rich secretory protein 3                                      | 2.39E-04   | Y      | Y      | N    | 27.4                                | 21.8                             | 0.6              |
| IGJ       | Immunoglobulin J chain                                                 | 2.83E-04   | Y      | Y      | N    | 29.8                                | 25.9                             | 0.8              |
| CTSB      | Cathepsin B; Cathepsin B light chain; Cathepsin B heavy chain          | 3.80E-04   | Y      | N      | N    | 25.4                                | 22.7                             | 0.6              |
| PIGR      | Polymeric immunoglobulin receptor; Secretory component                 | 4.62E-04   | Y      | N      | N    | 30.8                                | 27.3                             | 0.8              |
| LYZ       | Lysozyme C                                                             | 6.12E-04   | Y      | N      | N    | 33.4                                | 28.2                             | 1.2              |
| LGALS3BP  | Galectin-3-binding protein                                             | 6.57E-04   | Y      | N      | N    | 25.0                                | 22.1                             | 0.6              |
| NUCB2     | Nucleobindin-2                                                         | 7.02E-04   | Y      | N      | N    | 24.7                                | 21.8                             | 0.5              |
| DBMT1     | Deleted in malignant brain tumors 1 protein                            | 8.31E-04   | Y      | N      | N    | 29.4                                | 24.7                             | 1.1              |
| PIP       | Prolactin-inducible protein                                            | 1.87E-03   | Y      | N      | N    | 31.3                                | 26.6                             | 1.2              |
| IGHA2     | Immunoglobulin heavy constant alpha 2                                   | 1.99E-03   | Y      | N      | N    | 27.4                                | 24.6                             | 0.7              |
| FN1       | Fibronectin; Anastellin; Ugl-Y1; Ugl-Y2; Ugl-Y3                        | 2.07E-03   | Y      | N      | N    | 27.7                                | 24.2                             | 0.9              |
| MSLN      | Mesotheolin; Megakaryocyte-potentiating factor; Mesotheolin, cleaved form | 2.44E-03   | Y      | N      | N    | 25.7                                | 22.2                             | 0.9              |
| CLU       | Clusterin; Clusterin beta chain; Clusterin alpha chain; Clusterin     | 4.16E-03   | Y      | N      | N    | 27.3                                | 25.4                             | 0.6              |
| IGHA1     | Ig alpha-1 chain C region                                              | 5.33E-03   | Y      | N      | N    | 32.5                                | 30.0                             | 0.7              |
| B2M       | Beta-2-microglobulin; Beta-2-microglobulin form pl 5.3                 | 5.59E-03   | Y      | N      | N    | 28.2                                | 24.9                             | 1.0              |
| DBNL      | Drebrin-like protein                                                   | 6.22E-03   | N      | N      | N    | 21.5                                | 20.5                             | 0.3              |
| PRR4      | Proline-rich protein 4                                                 | 7.24E-03   | N      | N      | N    | 31.1                                | 24.5                             | 2.0              |
| IGHA2     | Ig alpha-2 chain C region                                              | 7.43E-03   | N      | N      | N    | 26.2                                | 23.2                             | 0.5              |
| PSAP      | Proactivator polypeptide; Saposin-A; Saposin-B-Val; Saposin-B; Saposin-C; Saposin-D | 7.65E-03   | N      | N      | N    | 24.0                                | 22.7                             | 0.4              |
| SLPI      | Antileukoproteinase                                                    | 9.52E-03   | N      | N      | N    | 27.1                                | 24.8                             | 0.8              |
| CBR1      | Carbonyl reductase [NADPH] 1                                            | 1.50E-02   | N      | N      | N    | 22.7                                | 20.8                             | 0.6              |
| TUBB4B; TUBB4A | Tubulin beta-4B chain; Tubulin beta-4A chain                  | 1.65E-02   | N      | N      | N    | 27.0                                | 25.2                             | 0.6              |
| RNI1      | Ribonuclease inhibitor                                                 | 1.69E-02   | N      | N      | N    | 23.0                                | 21.9                             | 0.3              |
| HNRNPK    | Heterogeneous nuclear ribonucleoprotein K                              | 2.08E-02   | N      | N      | N    | 24.1                                | 20.6                             | 1.1              |
| PRDX6     | Peroxiredoxin-6                                                        | 2.94E-02   | N      | N      | N    | 23.9                                | 22.0                             | 0.7              |
| IGHV3-7@  | Immunoglobulin heavy variable 3–7                                       | 3.30E-02   | N      | N      | N    | 22.6                                | 21.0                             | 0.7              |
Although classically described as a non-inflammatory disease [13, 23], recent research has shown altered inflammatory pathways and mediators in keratoconus corneas and tear film [9, 10, 24–27]. Despite extensive research, its complex genetic mechanisms are still elusive, with multiple gene/loci currently identified and different modes of inheritance reported [28]. Our study found 7 differentially expressed proteins in tears of keratoconus patients, 4 of which are related to immune responses (immunoglobulin chains and neutrophil defensin). These results suggest the involvement of immunologic pathways in keratoconus pathophysiology. As the specific disease mechanisms in keratoconus are still obscure, any insight from its tear proteomic profile could aid future research.

Ocular surface disease is not a main feature in keratoconus patients. However, a previous study showed altered clinical parameters like tear break-up time (BUT), fluorescein and rose Bengal staining scores and lower corneal sensitivity [17]. Our study found the least number of altered proteins in the keratoconus group, which correlates to the lesser impact on the ocular surface in comparison to pterygium and GVHD related dry eye. It could also be related to the lower number of keratoconus subjects compared to the other study groups. Although the results from the Student’s t-test were not significant after multiple comparisons correction, the multivariate analyses were able to differentiate the keratoconus tear proteome from the control group through the heat map dendrogram analysis and the PCA scores plot. These tear proteome alterations in keratoconus could be directly related to increased cytokine secretion by the corneal epithelium or a concomitant ocular surface disease condition.

To our knowledge, we report the first findings of tear proteome in pterygium patients, comparing to a control group. Among the proteins with altered expression, Prolactin-inducible protein was previously reported as reduced in dry-eye patients [29, 30], while the protein S100A8 (calgranulin) was reported as increased in dry eye patients [31]. In our sample, we found increased expression of keratin proteins in pterygium and GVHD tears, which may be related to the increased epithelial keratinization that may happen in these conditions.

The estrogen signaling pathway was retrieved from the biochemical pathway prospection of the pterygium tear proteome. In a large cross-sectional population-based study with postmenopausal women [32], Kyung-Sun et al. found decreased pterygia prevalence among women receiving estrogen replacement therapy, in comparison to those not receiving estrogen replacement. They hypothesized that estrogen in the tear film might protect the ocular surface from pterygium development by blocking oxidative stress-induced inflammation. Although it is not yet possible to establish a causative effect, alterations in the estrogen signaling pathway could be related to pterygium pathophysiology and warrant further research.

The GVHD tear proteome showed the most altered profile of differentially expressed proteins, and several among them had already been described in previous studies. Protein S100-A9 is a proinflammatory protein with increased levels in tears from dry eye patients and positively correlated to disease intensity [29]. Immunoglobulin gamma-3 chain C was also found upregulated in tears from dry eye patients [30]. Histones are a group of DNA-binding proteins involved in nucleosome assembly and also described as pro-inflammatory mediators, previously reported in increased levels in tear samples from...
Table 6 Student’s t-test analysis of tear proteome from patients diagnosed with ocular GVHD versus control

| Gene name | Protein                                                                 | p-value   | FDR 5% | FDR 1% | FWER 5% | Control average LFQ log transformed | GVHD average LFQ log transformed | SE of difference |
|-----------|-------------------------------------------------------------------------|-----------|--------|--------|---------|-------------------------------------|----------------------------------|------------------|
| TKT       | Transketolase                                                           | 2.75E−05  | Y      | Y      | Y       | 21.2                                | 25.4                             | 0.6              |
| DEFA1; DEFA3 | Neutrophil defensin 1; HP 1−56; Neutrophil defensin 2                  | 3.90E−05  | Y      | Y      | Y       | 24.7                                | 30.1                             | 0.9              |
| KRT13S    | Keratin, type I cytoskeletal 13                                         | 5.89E−05  | Y      | Y      | Y       | 25.8                                | 30.1                             | 0.8              |
| KRT4      | Keratin, type II cytoskeletal 4                                          | 6.68E−04  | Y      | N      | N       | 25.5                                | 28.9                             | 0.8              |
| KRT5      | Keratin, type II cytoskeletal 5                                          | 7.04E−04  | Y      | N      | N       | 26.2                                | 29.2                             | 0.7              |
| SAA4      | Serum amyloid A-4 protein                                                | 1.49E−03  | Y      | N      | N       | 22.6                                | 23.9                             | 0.3              |
| CASP14    | Caspase-14; Caspase-14 subunit p19; Caspase-14 subunit p10              | 2.43E−03  | Y      | N      | N       | 22.2                                | 25.2                             | 0.7              |
| ANXA1     | Annexin A1; Annexin                                                     | 2.47E−03  | Y      | N      | N       | 24.8                                | 27.1                             | 0.6              |
| KRT19     | Keratin, type I cytoskeletal 19                                          | 2.48E−03  | Y      | N      | N       | 25.6                                | 28.5                             | 0.8              |
| A2M       | Alpha-2-macroglobulin                                                   | 2.89E−03  | Y      | N      | N       | 26.1                                | 29.0                             | 0.8              |
| CFB       | Complement factor B; Complement factor B Ba fragment; Complement factor B Bb fragment | 3.20E−03  | Y      | N      | N       | 24.2                                | 26.9                             | 0.7              |
| KRT6A; KRT6C | Keratin, type II cytoskeletal 6A; Keratin, type II cytoskeletal 6C | 3.74E−03  | Y      | N      | N       | 28.1                                | 30.6                             | 0.7              |
| SPRR3     | Small proline-rich protein 3                                             | 4.04E−03  | Y      | N      | N       | 22.3                                | 24.9                             | 0.7              |
| PLG       | Plasminogen                                                              | 4.67E−03  | Y      | N      | N       | 22.7                                | 24.7                             | 0.5              |
| IGHM      | Ig mu chain C region; Ig mu heavy chain disease protein                 | 4.86E−03  | Y      | N      | N       | 26.3                                | 28.2                             | 0.6              |
| ANXA2; ANXA2P2 | Annexin A2; Annexin; Putative annexin A2-like protein | 5.22E−03  | Y      | N      | N       | 25.1                                | 27.7                             | 0.8              |
| HRG       | Histidine-rich glycoprotein                                              | 5.85E−03  | Y      | N      | N       | 21.7                                | 23.8                             | 0.6              |
| H2AFX#    | Histone H2AX                                                             | 6.76E−03  | N      | N      | N       | 22.0                                | 24.4                             | 0.7              |
| FLG       | Filaggrin                                                                | 6.93E−03  | N      | N      | N       | 21.8                                | 25.7                             | 1.2              |
| MYL6      | Myosin light polypeptide 6                                               | 8.11E−03  | N      | N      | N       | 21.9                                | 24.0                             | 0.7              |
| IGHG3     | Ig gamma-3 chain C region                                               | 9.38E−03  | N      | N      | N       | 27.4                                | 29.8                             | 0.8              |
| CTSG      | Cathepsin G                                                              | 9.40E−03  | N      | N      | N       | 20.3                                | 24.6                             | 1.3              |
| HIST1H4A  | Histone H4                                                               | 1.00E−02  | N      | N      | N       | 23.2                                | 25.2                             | 0.6              |
| CFH       | Complement factor H                                                      | 1.22E−02  | N      | N      | N       | 24.2                                | 26.4                             | 0.7              |
| YWHAZ     | 14−3-3 protein zeta/delta                                               | 1.25E−02  | N      | N      | N       | 24.7                                | 26.6                             | 0.6              |
| EZR       | Ezrin                                                                    | 1.80E−02  | N      | N      | N       | 24.6                                | 25.9                             | 0.5              |
| HSPA8     | Heat shock cognate 71 kDa protein                                        | 1.94E−02  | N      | N      | N       | 23.2                                | 25.0                             | 0.7              |
| ACTN4     | Alpha-actinin-4                                                          | 1.98E−02  | N      | N      | N       | 22.6                                | 25.0                             | 0.9              |
| LRG1      | Leucine-rich alpha-2-glycoprotein                                        | 2.05E−02  | N      | N      | N       | 21.9                                | 23.2                             | 0.5              |
| S100A14   | Protein S100-A14                                                         | 2.09E−02  | N      | N      | N       | 19.5                                | 21.7                             | 0.8              |
| KRT14     | Keratin, type I cytoskeletal 14                                          | 2.30E−02  | N      | N      | N       | 24.8                                | 27.8                             | 1.1              |
| C4BPA     | C4b-binding protein alpha chain                                         | 2.41E−02  | N      | N      | N       | 21.6                                | 23.7                             | 0.8              |
| TF        | Serotransferrin                                                          | 2.41E−02  | N      | N      | N       | 28.3                                | 30.9                             | 1.0              |
| YWHAB     | 14−3-3 protein beta/alpha; 14−3-3 protein beta/alpha, N-terminally processed | 2.51E−02  | N      | N      | N       | 23.7                                | 25.3                             | 0.6              |
| ITIH1     | Inter-alpha-trypsin inhibitor heavy chain H1                            | 2.58E−02  | N      | N      | N       | 21.8                                | 22.9                             | 0.4              |
| C3Φ       | Complement C3                                                            | 2.61E−02  | N      | N      | N       | 27.6                                | 29.2                             | 0.6              |
### Table 6 (continued)

| Gene name | Protein                        | p-value   | FDR 5% | FDR 1% | FWER Control average | LFQ log transformed | LFQ log transformed | SE of difference |
|-----------|--------------------------------|-----------|--------|--------|-----------------------|---------------------|---------------------|------------------|
| TFF1      | Trefoil factor 1               | 2.65E−02  | N      | N      | N                     | 22.9                | 25.8                | 1.1              |
| ALB       | Serum albumin                 | 2.82E−02  | N      | N      | N                     | 33.5                | 35.3                | 0.7              |
| ACTB      | Actin, cytoplasmic 1; Actin,  | 3.14E−02  | N      | N      | N                     | 27.3                | 29.0                | 0.7              |
| CFL1      | Cofilin-1                      | 3.62E−02  | N      | N      | N                     | 21.9                | 24.0                | 0.9              |
| KNG1      | Kininogen-1                    | 4.37E−02  | N      | N      | N                     | 23.8                | 25.3                | 0.7              |
| S100A9    | Protein S100-A9                | 4.40E−02  | N      | N      | N                     | 24.6                | 26.6                | 0.9              |
| UPK3BL;  | Uroplakin-3b-like protein      | 4.44E−02  | N      | N      | N                     | 21.9                | 23.0                | 0.5              |
| TXN       | Thioredoxin                    | 4.96E−02  | N      | N      | N                     | 22.9                | 24.7                | 0.8              |

Proteins with increased abundance in GVHD in comparison with controls are shown.
FDR: false discovery rate. FWER: family-wise error rate (Holm-Sidak method). Y: yes, still significant after multiple comparisons correction. N: no, not significant after multiple comparisons correction. SE: standard error. § keratin cluster (P13646-1; K7EQH6; P35900; K7EM2; A0A140TA66; Q8IUTB; O76011; Q6IFU5; Q6A162; O76009; Q6MTB9; O76009; A0A140TA62; O76011; G3V1C2; J3QR58). # histone cluster (H2AFX; HIST1H2AA; HIST1H2AB; HIST1H2AG; HIST1H2AD; HIST2H2AA3; HIST3H2A; HIST1H2AC; HIST2H2AC; H2AFJ; HIST1H2AH; HIST1H2AJ; HIST2H2AB; H2AFZ; H2AFY). Φ complement cluster (P01024; Q2UVX4; M0QKZ3; M0QVC8; M0ROQ9)

---

**Fig. 2** Estrogen signaling pathway with altered proteins in pterygium tear proteome in highlight. Red: increased quantification. Green: decreased quantification.
GVHD patients [11]. The proline-rich protein 4, found in decreased levels in tears from both GVHD and non-GVHD related dry eye, has been described as a product of the lacrimal gland, but its role on the ocular surface is not yet understood [6, 11, 31]. Lipocalin-1, a major component of normal tears, along with lysozyme C and lactotransferrin, both antimicrobial proteins, are produced by the lacrimal gland and are also downregulated in tears from dry eye patients [6, 11, 30]. Lacrimal gland dysfunction and fibrosis is a major feature of ocular GVHD [33], and it may explain the decreased level of the proteins discussed above. Interestingly, this downregulation of proteins with antibacterial activity like lysozyme and lactotransferrin may be related to the increased risk...
The complement and coagulation cascades were retrieved by the biochemical pathway prospection from the GVHD tear protein profile. Previous studies have shown complement activation in GVHD patients, and also in transplant-associated thrombotic microangiopathy (TA-TMA), another complication of hematopoietic stem cell transplantation [34]. Endothelial injury would be the trigger to the complement activation in these conditions. Plasma complement component 3b (C3b) has also been identified in increased levels in TA-TMA and GVHD patients [35]. We have also found increased levels of infectious diseases of the ocular surface in dry eye patients [29].

The complement and coagulation cascades were retrieved by the biochemical pathway prospection from the GVHD tear protein profile. Previous studies have shown complement activation in GVHD patients, and also in transplant-associated thrombotic microangiopathy (TA-TMA), another complication of hematopoietic stem cell transplantation [34]. Endothelial injury would be the trigger to the complement activation in these conditions. Plasma complement component 3b (C3b) has also been identified in increased levels in TA-TMA and GVHD patients [35]. We have also found increased levels of infectious diseases of the ocular surface in dry eye patients [29].

Table 7  Potential biomarkers in tears for keratoconus

| Protein | Full name                        |
|---------|----------------------------------|
| RARRES1 | Retinoic acid receptor responder protein 1 |
| PRR27   | Proline-rich protein 27          |
| CTSG    | Cathepsin G                      |
| MPO     | Myeloperoxidase                  |
| IGHM    | Immunoglobulin heavy constant mu |
| KRT13   | Keratin, type I cytoskeletal 13  |
| EZR     | Ezrin                            |
| IGHV5   | Immunoglobulin heavy variable 5  |

Biomarkers chosen after VIP-PLSDA (Variable Importance in Projection in Partial Least Scores Discriminant Analysis) multivariate analysis. Decreasing order of average importance

Fig. 5  Multivariate ROC analysis and potential biomarkers average importance for keratoconus group. a Area under curve (AUC) from multivariate ROC analyses and corresponding 95% confidence intervals (CI). b Predicted Class Probabilities. c Potential biomarkers displayed in order of average importance

Fig. 6  Heat map, PCA scores plot, and ROC curve for pterygium group. a Heat map, the colors indicate relative expression levels, with red colors for increased protein levels, and green colors for decreased protein levels. b PCA (principal component analysis) scores plot. c ROC (receiver operating characteristic) curve
of complement component 3 (C3) in GVHD tears. These findings suggest that the tear film of GVHD patients may reflect the systemic alterations in complement cascade found in this disease.

There are several methods for tear sample collection, such as glass microcapillary tubes [3, 8, 10], Schirmer test I strips [6, 9, 30], and eye-flush with sterile saline or distilled water [36–38]. In this study, the eye flush method was chosen because of the technical difficulty in obtaining tear samples from the severe dry eye related GVHD group using either microcapillary tubes or Schirmer strips. Although the eye flush method may generate lower protein concentrations, it has been reported to yield the same spectrum of proteins in similar proportions as basal...

Table 8 Potential biomarkers in tears for pterygium

| Protein | Full name                        |
|---------|----------------------------------|
| KRT78   | Keratin, type II cytoskeletal 78 |
| TYMP    | Thymidine phosphorylase          |
| C4A     | Complement C4-A                  |
| ANXA11  | Annexin A11                     |
| KRT14   | Keratin, type I cytoskeletal 14  |
| KRT13   | Keratin, type I cytoskeletal 13  |
| YWHAEE  | 14–3-3 protein epsilon           |
| HISTH4A | Histone H4                       |
| KRT5    | Keratin, type II cytoskeletal 5  |
| KRT6B   | Keratin, type II cytoskeletal 6B |

Biomarkers chosen after VIP-PLSDA (Variable Importance in Projection in Partial Least Scores Discriminant Analysis) multivariate analysis. Decreasing order of average importance.

Fig. 7 Multivariate ROC analysis and potential biomarkers average importance for pterygium group. a Area under curve (AUC) from multivariate ROC analyses and corresponding 95% confidence intervals (CI). b Predicted Class Probabilities. c Potential biomarkers displayed in order of average importance.

Fig. 8 Heat map, PCA scores plot, and ROC curve for GVHD group. a Heat map, the colors indicate relative expression levels, with red colors for increased protein levels, and green colors for decreased protein levels. b PCA (principal component analysis) scores plot. c ROC (receiver operating characteristic) curve.
or reflex tear collection [38]. All study subjects had the same tear collection technique.

Proteomics experiments yield a large quantity of data, usually hundreds of different proteins. There is much debate in the literature on how to deal with all this information and which are the best statistical tools. Saccenti et al. [39], in a review article about the use of univariate and multivariate analysis of metabolomics data, suggest that both methods should be used, as they provide complementary information, and this is the strategy we used to analyze our data. We observed that in our sample some proteins appeared in the multivariate analysis, specifically the partial least squares discriminant analysis (PLS-DA), but they were not significant in the univariate analysis (Student t-test). These results do not necessarily match, and sometimes we can find significant results multivariately and not univariately. As multivariate methods use all variables simultaneously, we have information about the simultaneous relationship among them. Independent variables may complement each other and give information that is not always available through univariate methods. These results could be seen as complementary rather than contradictory.

In our study design, we intended to evaluate the tear film of three very distinct ocular diseases—keratoconus, pterygium, and chronic GVHD related dry eye, using LC–MS for proteomic investigation. Our purpose herein was to investigate in a pilot comparative study if ocular conditions with entirely different mechanisms and clinical presentations could be differentiated by tear proteome. Although our study had a small sample size, we could still demonstrate that each disease has a characteristic tear proteomic profiling, and the multivariate analysis, particularly PCA, was a powerful tool to differentiate the four study groups, showing the feasibility of the technique for future research with a larger sample size. The candidate biomarkers presented here are preliminary and need further validation. By understanding how these different conditions can modify the tear film proteome, these data may help future biomarker research and also provide insights into the pathophysiology of keratoconus, pterygium, and GVHD related dry eye. We hope this work will stimulate other research groups to increase the knowledge about the mechanisms involved in such broad areas of ocular disease.

### Conclusions

We demonstrated herein that mass spectrometry-based proteomics was able to indicate proteins that differentiate three distinct ocular conditions: keratoconus, pterygium, and GVHD related dry eye. We also reported potential candidates as biomarkers for each disease.

---

**Table 9: Potential biomarkers in tears for GVHD related dry eye**

| Protein | Full name              |
|---------|------------------------|
| PRTN3   | Myeloblastin           |
| KRT13   | Keratin, type I cytoskeletal 13 |
| PLTP    | Phospholipid transfer protein |
| CHI3L2  | Chitinase-3-like protein 2 |
| LCN1    | Lipocalin-1            |
| JCHAIN  | Immunoglobulin J chain  |
| AZGP1   | Zinc-alpha-2-glycoprotein |
| LTF     | Lactotransferrin       |

Biomarkers chosen after VIP-PLS-DA (Variable Importance in Projection in Partial Least Scores Discriminant Analysis) multivariate analysis. Decreasing order of average importance.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12325-020-00307-5.

Additional file 1: Table S1. Proteins identified in keratoconus and control group tears. Gene names, protein names and ID, and Student’s t-test results comparing all proteins identified in keratoconus and control group.

Additional file 2: Table S2. Proteins identified in pterygium and control group tears. Gene names, protein names and ID, and Student’s t-test results comparing all proteins identified in pterygium and control group.

Additional file 3: Table S3. Proteins identified in GVHD and control group tears. Gene names, protein names and ID, and Student’s t-test results comparing all proteins identified in GVHD and control group.

Acknowledgements
We acknowledge the Mass Spectrometry Laboratory at Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, Brazil, for their support with the mass spectrometry analysis.

Authors’ contributions
All authors contributed in the conception and design of the study, critical revision of the article and in the final approval of the version to be published; data collection was done by DAB, BD, MV, MT, ACVW, experiments were performed by DAB, RRD, BD, MV, MT, data analysis and interpretation was performed by DAB, MRA, AFPL and MA; DAB, MRA, CELA and MA drafted the article. All authors read and approved the final manuscript.

Funding
This research was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), reference number 2014/19138–5, and by Fundo de Apoio ao Ensino, à Pesquisa e à Extensão (FAEPEX), reference number 3001/19. The funding body did not have any role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its additional files.

Ethics approval and consent to participate
The study was carried out with the approval of the Institutional Research Ethics Committee Board (CEP) of UNICAMP (reference number: 05904316.0.0000.5404) and was conducted under the tenets of the Declaration of Helsinki and current legislation on clinical research. Written informed consent was obtained from all subjects after explanation of the procedures and study requirements.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
2 Department of Cell Biology, University of Brasília, Brasília, Brazil.
3 Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, Brazil.

Received: 30 October 2019 Accepted: 27 November 2020 Published online: 07 December 2020

References
1. von Thun and Hohenstein-Blaul N, Funke S, Grus FH. Tears as a source of biomarkers for ocular and systemic diseases. Exp Eye Res. 2013;117:126–37.
2. Zhou L, Beuereman RW. Tear analysis in ocular surface diseases. Prog Retin Eye Res. 2012;31(6):527–50.
3. Grus FH, Joachim SC, Pfeiffer N. Proteomics in ocular fluids. Proteomics Clin Appl. 2007;1(8):876–88.
4. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198–207.
5. González N, Iloiro I, Soria J, Durán JA, Santamaria A, Elortza F, et al. Human tear peptide/protein profiling study of ocular surface diseases by SPE-MALDI-TOF mass spectrometry analyses. EuPA Open Proteomics. 2014;3:206–15.
6. Perumal N, Funke S, Pfeiffer N, Grus FH. Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. Sci Rep. 2016;6(July):1–12.
7. Li B, Sheng M, Xie L, Liu F, Yan G, Wang W, et al. Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. Invest Ophthalmol Vis Sci. 2014;55(1):177–86.
8. Pannebaker C, Chandler HL, Nichols JJ. Tear proteomics in keratoconus. Mol Vis. 2010;16(September):1949–57.
9. Lema L, Breu D, Rodríguez-González R, Díez-Feijoo E, Sobrino T. Proteomic analysis of the tear film in patients with keratoconus. Mol Vis. 2010;16(September):2055–61.
10. Balasubramanian SA, Wasinger VC, Pye DC, Willcox MD. Preliminary identification of differentially expressed tear proteins in keratoconus. Mol Vis. 2013;19:2124–34.
11. Hollbach NG, Plattner K, O’Leary OE, Jenoe P, Moes S, Drexlter B, et al. Tear film proteomics reveal important differences between patients with and without ocular GvHD after allogeneic hematopoietic cell transplantation. Investig Ophthalmol Vis Sci. 2018;59(8):3521–30.
12. Vazirani J, Basu S. Keratoconus: Current perspectives. Clin Ophthalmol. 2013;7:2019–30.
13. Rabinovitz YS. Keratoconus. Surv Ophthalmol. 1998;42(4):297–320.
14. Craig JP, Nichols KK, Akpek EK, Cornejo M, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.
15. Ogawa Y, Kurokawa M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22(Suppl 1):S19–27.
16. Chui J, Di Girolamo N, Wakefield D, Cornejo MT. The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf. 2008;6(1):24–43.
17. Dogru M, Karakaya H, Özgörün E, Ertürk H, Yucel A, Ozmam A, et al. Tear function and ocular surface changes in keratoconus. Ophthalmology. 2003;110(6):1110–8.
18. Julio G, Liuch S, Pujol P, Alonso S, Merindano D. Tear osmolarity and ocular changes in pterygium. Cornea. 2012;31(12):1417–21.
19. Rezvan F, Khazbkhooob M, Hooshmand E, Yekt A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol. 2018;63(5):719–35.
20. Winck FV, Ribeiro AC, Domingues RR, Ling LY, Riaño-Pachón DM, Rivera C, et al. Insights into immune responses in oral cancer through proteomic analysis of saliva and saliva extracellular vesicles. Sci Rep. 2015;5(5):1–13.
21. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9(2):280–99.
22. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. The KEGG database: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61.
23. Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol. 1984;28(4):293–322.
24. Shetty R, Ghosh A, Lim RR, Subramani M, Mihir K, Reshma AR, et al. Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. Investig Ophthalmol Vis Sci. 2015;56(2):738–50.
25. Balasubramanian SA, Mohan S, Pye DC, Willcox MDP. Proteases, proteolysis and inflammatory molecules in the tears of people with keratoconus. Acta Ophthalmol. 2012;90(4):303–9.
26. Acera A, Vecino E, Rodríguez-Agirrebe I, Aloria K, Arizmendi JM, Morales C, et al. Changes in tear protein profile in keratoconus disease. Eye. 2011;25(9):1225–33.
27. Jun AS, Cope L, Speck C, Feng X, Lee S, Meng H, et al. Subnormal cytokine profile in the tear fluid of keratoconus patients. PLoS ONE. 2011;6(1):1–8.
28. Michael A, Hauser JW. The genetics of keratoconus: a review. Reprod Syst Disord. 2012;01(02):1–8.
29. Zhou L, Beuerman RW, Choi MC, Shao ZZ, Xiao RL, Yang H, et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res. 2009;8(11):4889–905.
30. Srinivasan S, Thangavelu M, Zhang L, Green KB, Nichols KK. iTRAQ quantitative proteomics in the tears of dry eye patients. Invest Ophthalmol Vis Sci. 2012;53(8):5052–9.
31. Boehm N, Funke S, Wiegand M, Wehrwein N, Pfeiffer N, Grus FH. Alterations in the tear proteome of dry eye patients: A matter of the clinical phenotype. Invest Ophthalmol Vis Sci. 2013;54(3):2385–92.
32. Na KS, Jee DH, Han K, Park YG, Kim MS, Kim EC. The ocular benefits of estrogen replacement therapy: a population-based study in postmenopausal korean women. PLoS ONE. 2014;9(9):1–6.
33. Ogawa Y, Sjogren's syndrome, non-sjogren's syndrome, and graft-versus-host disease related dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):DE571–9.
34. Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259–66.
35. Qi J, Wang J, Chen J, Su J, Tang Y, Wu X, et al. Plasma levels of complement activation fragments C3b and iC3b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann Hematol. 2017;96(11):1849–55.
36. Lam SM, Tong L, Duan X, Petznick A, Wenk MR, Shui G. Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles. J Lipid Res. 2014;55(2):289–98.
37. Rentka A, Koroskenyi K, Harsfalvi J, Szekanecz Z, Szucs G, Szodoray P, et al. Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis. Ann Clin Biochem. 2017;54(S):S21–9.
38. Markoulli M, Papas E, Petznick A, Holden B. Validation of the flush method as an alternative to basal or reflex tear collection. Curr Eye Res. 2011;36(3):198–207.
39. Saccenti E, Hoeftsloot HJC, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. Metabolomics. 2014;10(3):361–74.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.